CYCC - Cyclacel Pharmaceuticals, Inc.
IEX Last Trade
0.324
0 0%
Share volume: 986
Last Updated: Fri 27 Dec 2024 08:29:45 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$0.32
0.00
0.00%
Fundamental analysis
25%
Profitability
25%
Dept financing
4%
Liquidity
50%
Performance
25%
Performance
5 Days
-0.34%
1 Month
-6.00%
3 Months
-68.51%
6 Months
-80.92%
1 Year
-88.82%
2 Year
-96.67%
Key data
Stock price
$0.32
DAY RANGE
$0.32 - $0.33
52 WEEK RANGE
$0.32 - $4.00
52 WEEK CHANGE
-$87.85
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: Spiro Rombotis
Region: US
Website: cyclacel.com
Employees: 14
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: cyclacel.com
Employees: 14
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Cyclacel Pharmaceuticals, Inc. develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) and CYC140. Sapacitabine, a nucleoside analog that is orally available prodrug of CNDAC, is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome.
Recent news